Guidelines for the Use of Parkinsonian Drugs (in USA)

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-56015-1_357-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine

  2018cited by this paper
• International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

  2018cited by this paper
• Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.

  2018cited by this paper
• Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease

  2018cited by this paper
• Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan

  2018cited by this paper
• Dopamine Agonists and Impulse Control Disorders: A Complex Association

  2017cited by this paper
• Monoamine Oxidase B Inhibitors in Parkinson's Disease.

  2017cited by this paper
• Safinamide: A Review in Parkinson’s Disease

  2017cited by this paper
• Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)

  2017cited by this paper
• Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

  2017cited by this paper
• ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

  2017cited by this paper
• Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

  2016cited by this paper
• Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.

  2016cited by this paper
• An update on the diagnosis and treatment of Parkinson disease

  2016cited by this paper
• Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE

  2016cited by this paper
• Long‐term effects of rasagiline and the natural history of treated Parkinson's disease

  2016cited by this paper
• Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database

  2015cited by this paper
• Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors

  2015cited by this paper
• Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

  2014cited by this paper
• Pharmacological treatment of Parkinson disease: a review.

  2014cited by this paper
• Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

  2014cited by this paper
• Withdrawing amantadine in dyskinetic patients with Parkinson disease

  2014cited by this paper
• An overview of adenosine A2A receptor antagonists in Parkinson's disease.

  2014cited by this paper
• Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

  2014cited by this paper
• Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.

  2014cited by this paper
• Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

  2014cited by this paper
• Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

  2014cited by this paper
• Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease

  2014cited by this paper
• Levodopa Fractionation in Parkinson's Disease

  2014cited by this paper
• Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

  2013cited by this paper
• Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2013cited by this paper
• Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

  2013cited by this paper
• Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

  2013cited by this paper
• Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.

  2013cited by this paper
• The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.

  2013cited by this paper
• Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial

  2012cited by this paper
• Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study

  2012cited by this paper
• Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone

  2012cited by this paper
• Extended-release pramipexole in advanced Parkinson disease

  2011cited by this paper
• Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease

  2011cited by this paper
• MAO-inhibitors in Parkinson's Disease

  2011cited by this paper
• Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

  2011cited by this paper
• Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

  2011cited by this paper
• Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

  2010cited by this paper
• Role of Pramipexole in the Management of Parkinson’s Disease

  2010cited by this paper
• Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease

  2009cited by this paper
• A review of ropinirole prolonged release in Parkinson’s disease

  2009cited by this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cited by this paper
• Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

  2009cited by this paper
• Levodopa/carbidopa/entacapone in Parkinson’s disease

  2009cited by this paper
• Levodopa for the treatment of Parkinson's disease.

  2008cited by this paper
• Update on the use of pramipexole in the treatment of Parkinson’s disease

  2008cited by this paper
• Dopamine agonist therapy in early Parkinson's disease.

  2008cited by this paper
• Advanced Parkinson disease treated with rotigotine transdermal system

  2007cited by this paper
• Ropinirole 24-hour prolonged release

  2007cited by this paper
• Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.

  2007cited by this paper
• Duodenal levodopa infusion for the treatment of Parkinson’s disease

  2007cited by this paper
• Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

  2007cited by this paper
• Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease

  2006cited by this paper
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2006cited by this paper
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]

  2006cited by this paper
• Utility of tolcapone in fluctuating Parkinson’s disease

  2006cited by this paper
• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  2005cited by this paper
• Entacapone in the treatment of Parkinson's disease.

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• The origin of motor fluctuations in Parkinson’s disease

  2004cited by this paper
• Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study

  2004cited by this paper
• Subcutaneous Apomorphine

  2004cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• Anticholinergics for symptomatic management of Parkinson's disease.

  2002cited by this paper
• New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET – [11C]raclopride study

  2002cited by this paper
• Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review

  2002cited by this paper
• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

  2002cited by this paper
• A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

  2001cited by this paper
• Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

  2001cited by this paper
• Early Parkinson’s Disease

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective.

  1999cited by this paper
• Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

  1999cited by this paper
• An algorithm (decision tree) for the management of Parkinson’s disease (2001):

  1998cited by this paper
• Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

  1998cited by this paper
• Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  1998cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way.

  1992cited by this paper
• Subcutaneous apomorphine in the treatment of Parkinson's disease.

  1990cited by this paper
• Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

  1988cited by this paper
• Treatment of Parkinson’s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches

  1984cited by this paper
• Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel)

  1975cited by this paper
• THE EFFECT OF ADDING AMANTADINE TO OPTIMUM L‐DOPA DOSAGE IN PARKINSON'S SYNDROME

  1973cited by this paper
• Amantadine in Parkinson's disease. Review of more than two years' experience.

  1972cited by this paper
• Dopamine: Release from the Brain in vivo by Amantadine

  1971cited by this paper

• A neoteric annotation on the advances in combination therapy for Parkinson’s disease: nanocarrier-based combination approach and future anticipation. Part I: exploring theoretical insights and pharmacological advances

  2024cites this paper
• Elucidating the molecular mechanism of phytochemicals against Parkinson’s disease through an integrated systems biology and molecular modeling approach

  year unknowncites this paper